Viewing affirmative mentions of gene expression of IL2 (H. sapiens) in bone marrow

Full-text article links are indicated by after the article reference.

Document Target Regulator Anatomy Sentence
Azogui et al. (1983)IL 2bone marrowInhibiton of IL 2 production after human allogeneic bone marrow transplantation.
Welte et al. (1984)interleukin 2bone marrowDefective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin 2.
Rossi et al. (1988)Interleukin 2bone marrowInterleukin 2 production in bone marrow of normal individuals and patients associated with B-cell chronic lymphocytic leukaemia.
Hicks et al. (2001)IL-2bone marrowHuman long-term bone marrow stromal cultures (LTBMC) have been transduced to express the immunostimulatory cytokine interleukin-2 (IL-2).
Ridgway and Borzy (1989)IL-2bone marrowThree of five treated patients had elevated IL-2 production at the time of bone marrow relapse.
Cooley (1987)IL 2bone marrowThis near normal production of IFN contrasts with our previous observation that IL 2 production in bone marrow transplant recipients is severely impaired for at least 6 mo post-transplant.
Yang (1997)IL-2bone marrowTo investigate IL-2 receptor (IL-2R) gene expression in acute myeloid leukemia (AML) cells and the role of IL-2 in AML, the IL-2R alpha mRNA and IL-2R beta mRNA in leukemic cells obtained from bone marrow of 41 cases with AML before chemotherapy were measured by reverse transcriptase-polymerase chain reaction (RT-PCR).
Rossi et al. (1988)IL2bone marrowIn this study, IL2 production was investigated in PB and in bone marrow (BM) from patients with previously untreated B-CLL, mostly in early stages of the disease, and compared to normal donors.
Warren et al. (1983)interleukin 2bone marrowHuman bone marrow allograft recipients: production of, and responsiveness to, interleukin 2.
Meloni et al. (1994)IL-2bone marrowThe administration of interleukin-2 (IL-2) may induce complete remissions in acute myelogenous leukemia (AML) patients with a low proportion of residual bone marrow (BM) blasts.
O'Brien et al. (1992)IL-2Bone marrowBone marrow granulomas are uncommon, but in the following case report we show their transient appearance after interleukin 2 (IL-2) and autologous lymphokine-activated killer cell therapy.
Russell et al. (1999)IL-2bone marrowHelper, interleukin 2 (IL-2) producing, T lymphocyte precursor (HTLp) frequency determination by limiting dilution analysis (LDA) is of value for quantifying alloreactivity in allogeneic bone marrow transplantation (BMT).
MacMillan et al. (2003)interleukin-2bone marrowHigh-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation.
Klingemann et al. (1993)interleukin-2bone marrowDesign and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts.
Hicks et al. (2001)interleukin-2bone marrowAdenoviral mediated interleukin-2 gene transfer to human long-term bone marrow stromal cultures.
Wang et al. (1998)IL-2bone marrowAfter stimulation of fresh T cells with PHA, an apparent increase in cytokine production was noted in IL-2 (35.5 +/- 8.3 pg/ml), IL-6 (1280.4 +/- 64.7 pg/ml), tumor necrosis factor-alpha (874.3 +/- 71.7 pg/ml), interferon-gamma (58.9 +/- 2.2 pg/ml), and granulocyte macrophage-colony-stimulating factor (59.5 +/- 4.4 colonies/5 x 10(4) bone marrow cells).
Imamura et al. (1990)IL-2bone marrowThereafter, an IL-2 production in these chimeras decreased around 45 days after bone marrow transplantation and then recovered nearly to the control level.
Zhu et al. (1998)rhIL-2bone marrow[TNF-alpha production and antitumor effect of rhIL-2-activated bone marrow cells].
Takatsuka et al. (2002)interleukin-2bone marrowThe levels of interleukin-2 and interleukin-2 receptor were determined in a group of patients undergoing bone marrow transplantation (BMT) without graft-versus-host disease or any other complications and in a group with cutaneous graft-versus-host disease (GVHD) alone.
Velardi et al. (1989)Lymphokinebone marrowLymphokine production by T-cell clones after human bone marrow transplantation.
Le Gros et al. (1987)IL 2bone marrowInterleukin 2 regulates the expression of IL 2 receptors on interleukin 3-dependent bone marrow-derived cell lines.
Baumhüter et al. (1985)IL 2bone marrowWhereas total syngeneic spleen cells and bone marrow macrophages could be shown to trigger proliferation, IL 2, and MAF production by the T cell clone, a B cell lymphoma only induced MAF secretion.
Condiotti and Nagler (1998)IL-2-activatedbone marrowIn the present study, we monitored the effect of IL-12 on the cytotoxic activity, proliferation, and phenotypic expression of HUCB-derived resting and IL-2-activated cytotoxic cells and compared these parameters with those of bone marrow (BM)-derived cells.
Maes et al. (1988)interleukin 2bone marrowA soluble factor produced by bone marrow natural suppressor cells blocks interleukin 2 production and activity.
Maes et al. (1988)IL-2bone marrowThus, these bone marrow natural suppressor cells produced a soluble factor, which regulated the growth of rapidly proliferating bone marrow cells and also regulated T cell reactivity by modulating IL-2 production and activity.
Gazzola et al. (1992)interleukin 2bone marrowRecombinant interleukin 3 induces interleukin 2 receptor expression on early myeloid cells in normal human bone marrow.
Gazzola et al. (1992)interleukin 2bone marrowWe found that IL-3 was able to induce the expression of interleukin 2 (IL-2) receptor (IL-2R) (CD25) on a subset of early myeloid cells in normal human bone marrow that had been first depleted of mature hematopoietic cells and E-rosette-positive T cells by treatment with soybean lectin and sheep erythrocytes (SBA-E-BM).
Møller et al. (1991)IL-2bone marrowSince CD29+ and CD57+ cells have a poor capability for IL-2 production and proliferation this shift in subset distribution may account for some of the defects in cellular immunity seen within the first year after allogeneic bone marrow transplantation.
Katsanis et al. (1991)IL-2bone marrowWe evaluated the proliferation, cytolytic function, and phenotypic characteristics of anti-CD3 plus interleukin-2 (IL-2) stimulated peripheral blood mononuclear cells (PBMCs) from 44 patients with leukemia or non-Hodgkin's lymphoma (NHL) treated with multiagent chemotherapy or following bone marrow transplantation (BMT).
Jia et al. (2002)IL-2bone marrowThe results showed that the expression of IL-2 in lymphocytes in 7 G-CSF mobilized donors decreased significantly after G-CSF administration and more severe aGVHD than grade II didn't develop in these recipient patients, and comparing with 15 patients received the bone marrow from donors who didn't receive G-CSF, the incidence of aGVHD decreased.
Carson et al. (1997)IL-2bone marrowNatural killer (NK) cells are bone marrow-derived lymphocytes that constitutively express the beta and common gamma(c) subunits of the IL-2 receptor (R) as a heterodimer with intermediate affinity for IL-2.
Kuroda et al. (2002)IL-2bone marrowLevels of IL-2, IL-6 and GM-CSF in bone marrow serum were significantly higher in all RA patients than in those with OA.
Kuroda et al. (2002)IL-2bone marrowIn patients with mutilans-type RA, IL-2 levels in the bone marrow serum were significantly higher than in patients with other types of RA or with OA.
Sanderson et al. (1985)lymphokinebone marrowTwo principal correlations were observed: IL-3 was shown to be the major lymphokine detected in the bone marrow proliferation assay (BMPA) used to detect CSF-2, and there was a high correlation between the EDA and BCGFII.
Isgrò et al. (2008)interleukin-2Bone marrowBone marrow cytokine production (interleukin-2 and tumor necrosis factor-alpha) and stromal interleukin-7 levels were analyzed by enzyme-linked immunosorbent assay in both groups.
Cooley et al. (1994)IL-2bone marrowPrevious studies from this laboratory have shown that PBMC from recipients of an HLA-identical sibling bone marrow transplant produce levels of IL-2 which are 10-100-fold lower than those produced by the same number of PBMC from healthy controls, whereas production of IFN-gamma is normal.
Tanaka et al. (1995)IL-2bone marrowIn this study, we have investigated cytokine (IL-1 beta, IL-2, IL-5, IL-6, IFN-gamma, TNF-alpha) and T cell surface molecule (IL-2 receptor, CD28, CTLA-4) gene expression in two way mixed lymphocyte cultures (MLC) enhanced by concanavalin A (ConA) to assess whether this is a useful predictive method for severe graft-versus-host disease (GVHD) and graft failure in allogeneic bone marrow transplantation (allo BMT) patients.
Shi et al. (1997)IL-2ABMThe optimum conditions for the activation of ABM and ACB were 1000U/ml IL-2, 1 x 10(6)/ml cells, 100 : 1 effector to target ratio and 72 hr culturing.
Melby et al. (2001)IL-2bone marrowUncontrolled parasite replication in the hamster liver, spleen, and bone marrow occurred despite a strong Th1-like cytokine (IL-2, IFN-gamma, and TNF/lymphotoxin) response in these organs, suggesting impairment of macrophage effector function.
Nisticò and Young (1994)lymphokinebone marrowLocal production of this inhibitory lymphokine in the target organ, the bone marrow, may be important in mediating aplastic anemia.
Darvay et al. (2004)IL-2bone marrowHowever, chronic GVHD is characterized by a relative deficiency of IL-2 and IFN-gamma producing cells compared with other patients post-bone marrow transplantation (BMT).
Zhu et al. (1994)IL-2bone marrowIncreased IL-2 and IFN-gamma mRNA expression were observed in 15-deoxyspergualin-treated bone marrow cells.
Takatsuka et al. (2000)interleukin-2bone marrowCompared with patients who did not develop severe intestinal GVHD after bone marrow transplantation, those who did had significantly higher interleukin-2 and interferon-gamma levels during the aplastic phase (P <0.01), followed by higher tumor necrosis factor-alpha levels during the recovery phase (P < 0.0001), with significant elevation of tumor necrosis factor-alpha and interferon-gamma occurring in association with exacerbations of intestinal GVHD (P < 0.001).
Mitsuyasu (1999)interleukin-2bone marrowIn the future, cytokines such as interleukin-2, vaccinations, cellular replacement or stem cell transfer, or bone marrow transplants may play important roles in therapy.